Overview
Whether you arrived from a “Injective vs REAL” query or from PEPS coin pages, this hub aggregates ranks, performance and module-backed signals into one canonical URL.
Quick winners
Full comparison
| Metric | INJ | REAL |
|---|---|---|
| Price | $5.01 | $1,856.75 |
| Market Cap | $490.41M | $244.34M |
| FDV | — | — |
| Volume 24h | $2.77M | $5.05M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 99.00 | 141.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.97% | +3.64% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | INJ | REAL |
|---|---|---|
| 1H | — | — |
| 24H | +2.04% | -0.10% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | INJ | REAL |
|---|---|---|
| RSI | 49.29 | 49.02 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.29 | 67.35 |
| ADX | 12.19 | 21.33 |
| Support | 4.91 | 1,827.82 |
| Resistance | 5.07 | 1,960.30 |
| Trend | neutral | bearish |
| Momentum | — | 67.00 |
| Signal | neutral | neutral |
Automatic technical analysis
Use the indicator table as a checklist: if momentum and trend align on one asset while the other diverges, relative-value setups become more interesting — still without certainty.
Fundamentals
| Metric | INJ | REAL |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | — |
| Github activity | 118.00 | — |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Injective
REAL
Pros and cons
Pros of Injective
- Higher ranking for Injective can translate into tighter spreads on major venues.
- Injective has an established coin page footprint on PEPS for continuous monitoring.
- Injective typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
Cons of Injective
- Large-cap status for Injective can mean slower percentage upside versus high-beta alternatives.
- Regulatory or macro headlines can hit Injective harder simply because it is more visible.
- Indicator stacks on Injective may stay stretched longer than expected in strong trends.
- When dominance narratives fade, Injective can lag hotter rotation names.
Pros of REAL
- Diversifying versus Injective with REAL can change portfolio factor exposure.
- Narrative optionality around REAL can reprice quickly when catalysts appear.
- REAL can offer higher relative beta when market attention rotates toward its niche.
Cons of REAL
- Trend failures on REAL often travel faster than on more established assets.
- Weaker market-cap standing may leave REAL more exposed to liquidity droughts.
- Higher volatility on REAL cuts both ways and demands stricter risk limits.
- Smaller book depth versus large caps can increase slippage for REAL.
Which looks stronger right now?
Statistically, higher market cap (Injective) often correlates with deeper books, while hotter 24h prints (Injective) can fade. Position sizing should reflect that uncertainty.
AI summary
This AI-assisted summary starts from live PEPS fields. Injective holds market-cap $490.41M and rank #99; REAL shows $244.34M and #141. Where liquidity and flow matter, watch REAL. Where durability matters, watch Injective. AI composite scores (47.20/57.90) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Injective or REAL?
“Better” depends on horizon and risk. Injective leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, INJ or REAL?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Injective and REAL.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. REAL currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.